Gyre Therapeutics, Inc. GYRE Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s other accrued liabilities?
- Gyre Therapeutics, Inc. (GYRE) reported other accrued liabilities of $226K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Gyre Therapeutics, Inc.'s other accrued liabilities decreased by 0.9% year-over-year, from $228K to $226K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s other accrued liabilities?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s other accrued liabilities has grown at a 24.4% compound annual growth rate (CAGR), from $118K to $227K.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.